This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of CDB-2914 for Emergency Contraception

This study has been completed.
Information provided by:
HRA Pharma Identifier:
First received: December 13, 2006
Last updated: June 16, 2010
Last verified: June 2010
The purpose of this study is to assess the safety and efficacy of CDB-2914 for preventing pregnancy when taken 3 to 5 days after unprotected sexual intercourse.

Condition Intervention Phase
Emergency Contraception Drug: CDB-2914 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CDB-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Sex

Resource links provided by NLM:

Further study details as provided by HRA Pharma:

Primary Outcome Measures:
  • Pregnancy rate

Secondary Outcome Measures:
  • Prevented fraction (number of prevented pregnancies divided by the number of expected pregnancies)
  • Impact on menstrual bleeding patterns
  • Frequencies of subjects with treatment emergent adverse events

Estimated Enrollment: 1320
Study Start Date: November 2006

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged 18 years or more
  • Menstruating women with regular menstrual cycle between 24 and 35 days and intra-individual variations less than or equal to 5 days
  • Request emergency contraception between 48 hours and 120 hours after unprotected intercourse as defined by lack of contraceptive use, or condom breakage (including condoms lubricated with spermicide) or other barrier contraceptive method failure
  • No current use of hormonal contraception and having had at least one complete menstrual cycle (2 menses) since having stopped hormonal contraception
  • For women with a recent history of Depo Provera use, the most recent injection must have been at least 9 months before study entry and followed by at least one complete menstrual cycle (2 menses)
  • Willing to not use hormonal methods of contraception until study completion
  • At least one complete menstrual cycle (2 menses) post delivery, miscarriage or abortion
  • Able to provide informed consent in English
  • Give voluntary, written informed consent, and agree to observe all study requirements (the subject needs to be available for follow-up over the next 6 weeks)
  • Willing to abstain from further acts of unprotected intercourse during participation in the study and until pregnancy status has been ascertained

Exclusion Criteria:

  • One or more acts of one unprotected intercourse more than 120 hours before requesting emergency contraception in the current cycle
  • All acts of unprotected intercourse (in the current cycle) within 48 hours of presentation
  • Currently pregnant as confirmed by positive HSUP test performed at screening
  • Currently breast-feeding
  • Current use of hormonal contraception
  • Use of hormonal emergency contraception since last menstrual period
  • Current use of IUD
  • Tubal ligation
  • Partner with a vasectomy
  • Unsure about the date of the last menstrual period
  • Severe asthma insufficiently controlled by oral glucocorticoid
  • Currently enrolled in any other trial of an investigational medicine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00411684

United States, California
Planned Parenthood of Mar Monte
San Jose, California, United States, 95126
United States, Colorado
Planned Parenthood of the Rocky Mountains
Denver, Colorado, United States, 80203
United States, Florida
Planned Parenthood of Greater Miami, Palm Beach and Treasure Cost
Miami, Florida, United States
Planned Parenthood of South Palm Beach, Pembroke Pines
Pembroke Pines, Florida, United States
United States, Indiana
Planned Parenthood of Indiana
Bloomington, Indiana, United States
United States, Iowa
Planned Parenthood of Greater Iowa
Ames, Iowa, United States
United States, Maryland
Planned Parenthood of Maryland
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Planned Parenthood League of Massachusetts
Boston, Massachusetts, United States, 02215
United States, Michigan
Planned Parenthood of Mid-Michigan Alliance
Ann Arbor, Michigan, United States
United States, Minnesota
Planned Parenthood of Minnesota
Minneapolis, Minnesota, United States
United States, Ohio
Planned Parenthood of Greater Cleveland
Cleveland, Ohio, United States
United States, Oregon
Planned Parenthood of Columbia-Willamette
Portland, Oregon, United States, 97206
United States, Pennsylvania
Planned Parenthood of SE Philadelphia
Philadelphia, Pennsylvania, United States
United States, Texas
Planned Parenthood of the Texas Capital Region
Austin, Texas, United States
Planned Parenthood of Houston and Southeast Texas
Houston, Texas, United States, 77004
United States, Utah
Planned Parenthood Association of Utah
Salt Lake, Utah, United States
United States, Washington
Planned Parenthood of Western Washington
Seattle, Washington, United States, 98122
Sponsors and Collaborators
HRA Pharma
Principal Investigator: Paul Fine, MD Planned Parenthood of Houston and Southeast Texas
  More Information

Publications: Identifier: NCT00411684     History of Changes
Other Study ID Numbers: 2914-005
Study First Received: December 13, 2006
Last Updated: June 16, 2010

Additional relevant MeSH terms:
Disease Attributes
Pathologic Processes processed this record on September 21, 2017